Targeting PLN (particularly distinct from phosphorylated forms) with intrabodies provides an accurate and efficient approach to modifying cellular physiology for the aforementioned PLN mutation-associated cardiomyopathy and other cardiac disease associated with dysregulation of PLN activity. This evidence concerns the gene PLN and heart disorder.